Moderna and Merck have developed a personalized mRNA cancer vaccine, intismeran autogene, which reduced the recurrence of melanoma when used alongside the immunotherapy drug Keytruda. According to a report, the vaccine succeeded in a late-stage clinical trial, marking a significant advancement in using mRNA technology to train the immune system to identify and destroy specific tumor cells.
How Personalized mRNA Vaccines Target Melanoma
Unlike traditional vaccines that prevent infectious diseases, mRNA cancer vaccines are therapeutic tools designed for patients already diagnosed with cancer. mRNA technology delivers genetic instructions that prompt the body’s cells to produce specific proteins found on the surface of tumor cells. This process teaches the immune system to recognize and attack those proteins, allowing the body to kill tumor cells without harming healthy tissue.
The vaccine intismeran autogene is personalized, meaning it is tailored to the specific genetic mutations of an individual patient’s tumor. This precision is intended to prevent the cancer from recurring after the initial surgical removal of the tumor and subsequent treatment with Keytruda.
Clinical Applications and Future Research
The success in melanoma is part of a broader effort to apply mRNA technology to various aggressive malignancies. Since the early 2000s, more than 120 clinical trials have tested mRNA vaccines for several types of cancer, including:
- Lung cancer
- Breast cancer
- Prostate cancer
- Brain cancer (specifically glioblastoma)
In the case of glioblastoma, an aggressive brain tumor with few existing treatments, researchers found that personalized mRNA vaccines could rapidly activate the immune system and improve patient survival rates.
Addressing mRNA Misinformation in Oncology
Medical researchers face a significant hurdle in public perception due to misinformation surrounding mRNA technology. The spread of “turbo cancer,” a false claim circulating on social media suggesting that COVID-19 mRNA vaccines cause aggressive cancers, is highlighted. This narrative lacks credible scientific evidence but has impacted public confidence in medical advancements.
The report notes that these inaccuracies occasionally enter mainstream discourse. For example, a September 2025 instance is cited where a U.K. cardiologist claimed the COVID-19 vaccine contributed to cancer diagnoses within the British royal family, a claim that drew immediate backlash from the medical community.
Comparison of mRNA Vaccine Functions
| Feature | Infectious Disease Vaccines (e.g., COVID-19) | Therapeutic Cancer Vaccines (e.g., Intismeran Autogene) |
|---|---|---|
| Primary Goal | Prevent infection by priming the immune system against a virus. | Treat existing cancer and prevent recurrence. |
| Target | Standardized viral proteins common to all infected people. | Personalized proteins unique to a patient’s specific tumor. |
| Application | Administered to healthy populations for prevention. | Administered to patients after initial cancer treatment. |
Related reading